Recent Updates
Recently added Catalysts
INSM Positive Sentiment

Insmed to Present at September 2026 Investor Conferences

Key Takeaway: Insmed Incorporated announced its participation in two upcoming investor conferences in September 2026. The 12th Annual Cantor Fitzgerald Global Healthcare Conference will take place on September 9, followed by the 24th Annual Morgan Stanley Global Healthcare Conference on September 14. Both events will be webcasted live and archived for 30 days.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is presenting at two major investor conferences.
  • The company is recognized as a top employer in the biopharmaceutical industry.
  • Insmed is advancing a diverse portfolio of therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.7%
average across 4 past catalysts
Cash runway
~39 mo
Minimal dilution risk
Lead asset
Brensocatib
Phase 3 · Non-Cystic Fibrosis Bronchiectasis

Full Press Release Details

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:
• 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET.
• 24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET.
These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Frequently Asked Questions

When will Insmed present at investor conferences?

Insmed will present on September 9 and September 14, 2026.

Where can I watch Insmed's presentations?

The presentations will be webcasted live on Insmed's investor relations website.

What is Insmed known for?

Insmed focuses on delivering first- and best-in-class therapies for serious diseases.

How long will the webcasts be available?

The webcasts will be archived for 30 days after the live events.

Last updated: Aug 26, 2026